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processing of V3 env ultra-deep 
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Jacques Izopet1,2,3 & Pierre Delobel2,3,4
HIV-1 coreceptor usage must be accurately determined before starting CCR5 antagonist-based 
treatment as the presence of undetected minor CXCR4-using variants can cause subsequent 
virological failure. Ultra-deep pyrosequencing of HIV-1 V3 env allows to detect low levels of CXCR4-
using variants that current genotypic approaches miss. However, the computation of the mass of 
sequence data and the need to identify true minor variants while excluding artifactual sequences 
generated during amplification and ultra-deep pyrosequencing is rate-limiting. Arbitrary fixed cut-
offs below which minor variants are discarded are currently used but the errors generated during 
ultra-deep pyrosequencing are sequence-dependant rather than random. We have developed an 
automated processing of HIV-1 V3 env ultra-deep pyrosequencing data that uses biological filters 
to discard artifactual or non-functional V3 sequences followed by statistical filters to determine 
position-specific sensitivity thresholds, rather than arbitrary fixed cut-offs. It allows to retain 
authentic sequences with point mutations at V3 positions of interest and discard artifactual ones 
with accurate sensitivity thresholds.
Human immunodeficiency virus type 1 enters CD4-expressing cells using one or both of the host cell 
coreceptors, CCR5 and CXCR41–3. Virus strains that specifically use CCR5 or CXCR4 are termed R5 or 
X4 variants, while those that use both coreceptors are termed dual/mixed variants (D/M)4.
Maraviroc is the first CCR5 antagonist approved for treating HIV-1 infections5. But the HIV-1 core-
ceptor usage must be determined to establish that a patient is not harboring CXCR4-using viruses and 
is thus eligible for CCR5 antagonist treatment6,7.
Recombinant virus phenotypic entry assays are now considered to be the gold-standard for determin-
ing HIV-1 tropism8–13. These assays can detect minor CXCR4-using variants down to 0.3–0.5% of the 
virus population8,14. However, their routine use is hampered by technical and cost limitations. Simple 
alternative genotypic approaches have been developed to infer virus tropism from the V3 env amino acid 
sequence15–19. Particularly, the presence of basic residues at V3 positions 11 and/or 25 and an increased 
net electrostatic charge of V3 have been associated with CXCR4 usage15,20,21. Genotypic algorithms based 
on the V3 env sequence perform well for predicting virus tropism when they are used at a clonal level21. 
However, direct sequencing of bulk PCR products of V3 env at a population level cannot detect minor 
CXCR4-using viruses that account for less than about 20% of the quasispecies21–23. Failure to detect 
CXCR4-using variants initially present at low frequencies in the virus population may lead to their 
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subsequent selection under CCR5 antagonist-based treatment24,25. Thus, there is a need for new genotypic 
techniques for determining tropism that are sensitive enough to detect minor CXCR4-using variants.
The sequencing of V3 env amplicons at high coverage with long read lengths has made massive par-
allel amplicon pyrosequencing using the 454 technology a promising tool for studying the virus diversity 
in clinical samples. It competes with ultra-sensitive phenotypic approaches for detecting low levels of 
CXCR4-using variants that current genotypic approaches miss, while being able to quantify the propor-
tion of each variant in the virus quasispecies24,26–36.
However, processing the mass of sequence data and the need to identify true minor variants while 
excluding artifactual sequences is the rate-limiting step in the process. Arbitrary fixed cut-offs (1–2%) 
are currently used, below which minor variants are discarded, but the errors generated during ultra-deep 
pyrosequencing are sequence-dependant rather than random, notably in homopolymeric regions37.
We have developed an automated position-specific processing of V3 env ultra-deep pyrosequencing 
data for rapidly inferring HIV-1 tropism with improved detection of minor variants (PyroVir software). 
It uses a sequence of logic rules based on the V3 sequence to discard artifactual or non-functional 
sequences with frame shifts or stop codons (biological filters), followed by a position-specific matrix 
based on Poisson distribution (statistical filter) to discard sequences with artifactual point mutations at 
V3 positions of interest. A particular attention had also been paid to provide a representative description 
of the virus quasispecies by limiting sampling and amplification bias prior to ultra-deep pyrosequencing.
Results
Optimized amplification steps before ultra-deep pyrosequencing for accurate representa-
tion of HIV-1 quasispecies. We determined experimentally the number of PCR cycles for which the 
amplification of a given input of virus copies remains linear without distorting the proportions of minor 
and major variants in the quasispecies. We found that 34 cycles of RT-PCR for an input of 2,000–3,000 
copies followed by 25 cycles of nested PCR were adequate to get high sensitivity without biasing the 
proportions in the virus population (Supplementary Fig. S1).
Performances of ultra-deep pyrosequencing for detecting CXCR4-using variants in HIV-1 qua-
sispecies compared to an ultrasensitive phenotypic assay. Three artificial mixtures of culture 
supernatants of pure X4 and R5 clones (LAI:JR-CSF; AFG4:AFG1, CHS2:CHS11) with defined pro-
portions of X4:R5 viruses (0:100; 0.5:99.5; 1:99; 5:95; 20:80; 50:50; 75:25; and 100:0) were submitted in 
parallel to ultra-deep pyrosequencing and phenotyping. The TTT phenotypic assay detected 0.5% of X4 
viruses in the LAI:JR-CSF mixture (1/3 replicates), 0.5% of X4 viruses in the AFG4:AFG1 mixture (1/3 
replicates), and 0.5% of X4 viruses in the CHS2:CHS11 mixture (3/3 replicates). Ultra-deep pyrosequenc-
ing of the same mixtures detected 0.5% of X4 viruses in the LAI:JR-CSF mixture (2/3 replicates), 0.5% 
of X4 viruses in the AFG4:AFG1 mixture (2/3 replicates), and 1% of X4 viruses in the CHS2:CHS11 
mixture (2/3 replicates). Our optimized process of amplification before ultra-deep pyrosequencing thus 
accurately described the HIV-1 quasispecies, with a 0.5–1% sensitivity for detecting CXCR4-using vari-
ants without distorting the proportions in the virus population (Table 1).
Automated data cleaning of errors occurring during the ultra-deep pyrosequencing pro-
cess. Ultra-deep pyrosequencing can generate errors that are sequence-dependant, notably in homopol-
ymeric regions, rather than random. Our automated approach distinguishes authentic variants from 
artifactual ones resulting from errors arising during PCR amplification and ultra-deep pyrosequencing.
Biological filters to discard non-functional V3 sequences. The sequences from the 454 ultra-deep pyrose-
quencing data were first processed with GS Amplicon Variant Analyzer (AVA) software (Roche). We did 
not use the AVA software cleaning filters that discard sequences under a fixed cut-off. Instead, the AVA 
X4 input 
(%)
X4 quantification in X4:R5 virus mixtures (%)
LAI:JR-CSF* AFG4:AFG1* CHS2:CHS11*
0.5 0.5 0.0 0.6 0.7 0.7 0.0 0.0 0.0 0.0
1.0 1.7 0.0 1.0 0.9 1.1 1.0 0.6 0.5 0.0
5.0 2.3 2.6 2.0 5.3 5.4 7.1 5.0 4.2 5.3
20.0 9.2 1.8 2.5 21.4 23.4 — 30.0 25.2 —
50.0 57.8 43.9 40.7 53.2 56.2 — 56.2 53.1 —
75.0 73.6 78.3 79.3 74.3 70.8 — 80.6 81.6 —
100.0 100.0 100.0 100.0 100.0 100.0 — 100.0 100.0 —
Table 1. Quantifying X4 variants in HIV-1 quasispecies by ultra-deep pyrosequencing. *Each virus 
mixture was assessed in triplicate or duplicate beyond 5%
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alignments were extracted, truncated to the V3 env region, and gaps were removed. Reads with unde-
termined bases were discarded. Reads were then temporary translated into amino acid sequences in the 
right open reading frame in order to discard V3 sequences considered as non-functional if (i) they did no 
start and end with the cysteine required for the disulfide bound maintaining the V3 loop; (ii) they were 
not 32–38 amino-acids long; (iii) they contained a stop codon; (iv) they were not sufficiently identical 
with the V3 consensus at three typical motifs: a “CTRP”-like signature at the N-terminus (V3 residues 
1–4), a “GPGR”-like signature at the hairpin crown (V3 residues 15–18), or a “QAHC”-like signature at 
the C-terminus (V3 residues 32–35). An identity of 0.5 and 0.75 was allowed for substitution and inser-
tion/deletion of an amino-acid at any of the three signature motifs (Fig. 1). The biological filters mainly 
discard sequences with frame shifts due to insertions/deletions of nucleotides in homopolymeric regions 
or stop codons. This step removed 5.7% (mean) of V3 reads.
Statistical filters to discard sequences with artifactual point mutations. The statistical filters assessed the 
probability that a sequence with a point mutation at a position of interest for predicting coreceptor usage 
would be artifactual or authentic. We first determined the frequency of artifactual V3 variants among the 
reads of 20 virus clones whose Sanger sequences were used as reference. The mean frequency of artifac-
tual V3 variants was 0.646% [exact Poisson 99% confidence interval (CI), 0.00560–0.00742] of the reads. 
We defined the global error rate as the upper 99% confidence interval limit of this mean frequency of 
artifactual V3 variants. Based on this global error rate of 0.742% (μ ), we estimated the expected number 
of artifactual sequences (λ) for N reads (λ = N * μ). We then used Poisson distribution to determine 
the minimum threshold above which a minor variant could be considered authentic for a given number 
of reads with P < 0.001. This fixed cut-off provided sensitivity thresholds from 1.7% for 1,000 reads to 
1.14% for 5,000 reads.
However, only a few key V3 amino-acid residues significantly influence the prediction of CXCR4 
coreceptor usage by genotypic algorithms. As the errors generated during ultra-deep pyrosequencing 
are sequence-dependant, arbitrary fixed cut-offs are not ideal for distinguishing authentic variants from 
artifactual ones. We have determined position-specific error rates along the V3 sequence, defined as the 
upper 99% confidence interval limit (Poisson statistics) of the mean frequency of artifactual codons at 
each V3 position among the 20 virus clones. The error rate varied greatly along the V3 sequence (Fig. 2). 
V3 position 20 had the highest error rate, followed by positions 19, 22, 21, 26, 18, and 11. We determined 
the percentage at which a given V3 position contributed to the mean error rate along V3. We then attrib-
uted a weighted error rate (ratio to 0.02857 – value if errors occurred constantly along the 35 positions 
of V3 - multiplied by the global error rate of 0.00742) at each position. These weighted error rates were 
Figure 1. PyroVir flowchart. 
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used to construct a sensitivity threshold matrix for each position of V3 to retain a minor virus variants 
harboring a point mutations as authentic for a given number of reads with P < 0.001 (Table 2).
Genotypic prediction of HIV-1 tropism. The genotypic prediction of CXCR4-tropism for a given 
V3 sequence must take into account several amino-acids of interest. We identified the positions at which 
amino acid K, R, D and E were present within a given sequence. The detection thresholds at these par-
ticular positions were defined for a given number of reads. A single threshold was then defined for each 
putative CXCR4-using variant, based on the criteria of the combined 11/25 and net charge rule which 
are necessary and sufficient to predict CXCR4 tropism (Table 3). This was then used to retain a sequence 
predicted to be CXCR4-tropic whose frequency was above the specific threshold defined for this particu-
lar sequence at a given number of reads. The statistical filter for the sensitivity threshold of sequences 
predicted to be CCR5-tropic (i.e. those having no criteria of the combined 11/25 and net charge rule) 
was based on the global error rate of the whole V3 region (μ = 0.00742), as defined above.
PyroVir software. This biological and statistical data cleaning strategy has been integrated in a pro-
gram (PyroVir, IDDN FR.001.160011.000.S.P.2012.000.31230, Inserm-Transfert) that provides a fast, auto-
mated position-specific process for inferring HIV-1 tropism from V3 env 454 ultra-deep pyrosequencing 
data with improved detection of minor variants. The genotypic rule used to predict CXCR4-usage can 
be changed depending on the virus subtype, particularly for subtypes D and CRF01-AE for which we 
have developed specific algorithms38,39. An example of HIV-1 quasispecies coreceptor usage prediction by 
PyroVir is shown in Fig. 3. PyroVir is accessible at http://diag.ablsa.com/pyrovir/submit.php.
Discussion
HIV-1 quasispecies coreceptor usage must be accurately determined before starting CCR5 antagonist-based 
antiretroviral therapy, as the presence of undetected minor CXCR4-using variants can lead to subsequent 
virological failure24,25. The development of gene therapy targeting CCR5 on hematopoietic stem cells in 
the quest for HIV cure would also require sensitive detection of CXCR4-using variants. Recombinant 
virus phenotypic entry assays are sensitive (0.3–0.5%) and considered to be the gold standard, but these 
assays are labour-intensive and expensive8,14. Genotypic methods based on bulk sequencing of V3 env 
combined with bioinformatics tools for inferring HIV-1 tropism are more rapid and more economical 
than phenotypic tests. But these simple genotypic assays are not sensitive enough to detect below 20% 
of minor CXCR4-using variants21–23. Ultra-deep pyrosequencing provides genotypic sensitivities similar 
to those of the current phenotypic assays, and also quantifies the proportion of each variant in the virus 
quasispecies. Ultra-deep pyrosequencing also has the advantage of using genotypic algorithms at a clonal 
level where genotype-phenotype correlations are better than for virus populations21. The PCR amplifica-
tion step is an important potential source of artifacts, such as substitutions and recombinations, that can 
be minimized by an optimized amplification40–42. The Taq polymerase enzyme used has an important 
impact on the proportion of correct reads after sequencing43. But adequate representation of the virus 
quasispecies should also be preserved and this requires the use of a reduced number of PCR amplifi-
cation cycles with a normalized virus input to ensure that the amplifications of both major and minor 
variants in the quasispecies are still in the logarithmic phase when the reaction is stopped.
Ultra-deep pyrosequencing of HIV-1 V3 env allows to detect low levels of CXCR4-using variants that 
current genotypic approaches miss. However, the extremely large data sets produced pose challenging 
computational problems, particularly the need to clean up the sequences by removing artifactual errors 
generated during amplification and pyrosequencing. Our PyroVir software rapidly and reliably predicts 
HIV-1 coreceptor usage from 454 ultra-deep pyrosequencing data. It has two modules. The first, biological 
Figure 2. Error rate of amplification and ultra-deep pyrosequencing at each position of the V3 
sequence. The mean error rate of amplification and pyrosequencing was estimated at each position of V3 
by comparing the pyrosequencing reads to the Sanger sequences of 20 clones. The mean error rate is shown 
with exact Poisson 99% confidence interval at each position of the V3 sequence.
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Table 2.  V3 position-specific matrix of sensitivity thresholds.
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case
Criteria of the combined 11/25 and net charge rule for HIV-1 subtype B
retained threshold
25R and net charge* ≥ +5 net charge* ≥ +6
11R or 
11K 25K
25R and net 
charge = +5
25R and net 
charge > +5† net charge = +6 net charge > +6‡
1 x position 11
2 x position 25
3 x maximum§
4 x maximum†,§
5 x maximum¶
6 x maximum‡,¶
7 x x minimum#
8 x x minimum§,||
9 x x minimum†,§,||
10 x x minimum¶,**
11 x x minimum‡,¶,**
12 x x minimum¶,††
13 x x minimum‡,¶,††
14 x x x minimum¶,‡‡
15 x x x minimum‡,¶,‡‡
Table 3.  Determining a single sensitivity threshold necessary and sufficient for predicting CXCR4-
usage according to the combined 11/25 and net charge rule. *The V3 net charge was calculated by 
subtracting the number of negatively charged amino acids (D and E) from the number of positively charged 
ones (K and R). †The most pejorative positions harboring a positively charged residue were eliminated 
to reach the criterion << 25R and net charge = + 5 >>. Alternatively, position 25 can be eliminated to 
arrive at the criterion << net charge = + 6 >> if more favorable. ‡The most pejorative positions harboring 
a positively charged residue were eliminated to arrive at the criterion << net charge = + 6 >>. §The most 
pejorative threshold between that of position 25 and those required for a net charge of + 5 is used. ¶The 
most pejorative threshold of the positions harboring a positively charged residue was used. #The least 
pejorative threshold between those of positions 11 and 25 is used. ||The least pejorative threshold between 
that of position 11 and those required for the << 25R and net charge = + 5 >> criterion is used. **The least 
pejorative threshold between that of position 11 and those required for a net charge of + 6 is used. ††The 
least pejorative threshold between that of position 25 and those required for a net charge of + 6 is used. 
‡‡The least pejorative threshold between those of positions 11, and 25, and those required for a net charge of 
+ 6 is used.
filters, discard artifactual and non-functional sequences, particularly those due to frame-shifts generated 
by insertions or deletions of nucleotides in homopolymeric regions or stop codons. The second, statistical 
filters based on Poisson distribution, discard artifactual point mutations. This method is position-specific 
and does not use arbitrary fixed cut-offs to discard sequences with artifactual point mutations at V3 
positions of interest as the errors generated during ultra-deep pyrosequencing are sequence-dependant. 
We found that the error rate of ultra-deep pyrosequencing varied along the V3 sequence, being max-
imum around V3 position 20. PyroVir automatically determines the sensitivity threshold for a given 
number of reads at each of the V3 positions involved in predicting CXCR4-usage, and then retains 
the highest threshold of the critical positions necessary and sufficient for predicting that a sequence is 
CXCR4-using. Subtype-specific algorithms could be used, especially for non-B subtypes such as subtypes 
D and CRF01-AE38,39,44. Arbitrary fixed cut-offs are currently used for cleaning up ultra-deep pyrose-
quencing data, usually 1 to 2%, below which sequences are discarded. These cut-offs have been deter-
mined based on rough error rates of ultra-deep pyrosequencing, and virological response rates in clinical 
studies with a limited number of patients34. Our results show that position-specific thresholds must be 
used to reliably detect minor variants. The sensitivity threshold varies greatly for a given number of reads 
(0.4 to 6.2% for 5,000 reads), depending on the V3 positions critical for CXCR4 usage. Therefore, using 
a fixed cut-off could result in a lack of sensitivity for some variants if the V3 positions involved have low 
error rates or even to false positives if the error rate is high.
The clinical relevance of minor variants is a matter of debate but should be distinguished from the 
analytical sensitivity of the method used. Previous studies reported cases of virological failure under 
CCR5 antagonists due to minor variants < 1%24, while other found that a 2% cut-off optimally predicted 
the clinical response34. Most of the data on the relevance of minor variants in HIV drug resistance have 
been reported in studies of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Minor variants at 
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frequencies of < 0.5% have been demonstrated to have a clinical impact on the virological response45. It 
has also been suggested that absolute numbers of resistant viruses are more clinically relevant than their 
frequencies for assessing the risk of subsequent virological failure. The measured frequency of viruses 
harboring a mutation associated with drug resistance should thus be multiplied by the plasma virus load 
to determine the absolute numbers of resistant viruses per mL of plasma. Minor resistant viruses in 
concentrations of 10–99 copies/mL were found to have a statistically significant impact on the virological 
response to NNRTIs, while concentrations of 1–9 copies/mL did not45. Interpretations of the impact of 
minor resistant viruses on the virological response are subject to additional caveats, notably the fitness 
and infectivity of the minor resistant viruses, and the effectiveness of the other molecules included in 
the combined antiretroviral regimen given to the subject. Analysis of the response to CCR5 antagonists 
is further complicated by the antiviral effect of CCR5 antagonists on R5 × 4 dualtropic variants in which 
CCR5 usage is more important than that of CXCR4 (<< dualR5 >> variants)46.
To summarize, we have developed an optimized process for the undistorted amplification and 
ultra-sensitive characterization of the coreceptor usage of HIV-1 quasispecies using ultra-deep pyrose-
quencing. This automated approach uses biological filters to discard artifactual or non-functional V3 
sequences followed by statistical filters to determine position-specific sensitivity thresholds to identify 
authentic sequences with point mutations at V3 positions of interest.
Methods
Sample processing. The HIV-1 RNA in plasma samples was quantified with COBAS Ampliprep/
COBAS TaqMan HIV-1 test version 2.0 (Roche). Plasma samples with a virus load of < 10,000 copies/
ml were ultracentrifuged at 20,000 g for 2h to concentrate the virus and RNA was extracted using the 
QIAamp Viral RNA Mini Kit (Qiagen). The initial input was adjusted to 2,000–3,000 copies of virus 
per PCR reaction, performed in duplicate, to avoid sampling bias. A lower input (300 copies) results in 
greater variability in the initial RT-PCR amplification for viruses at low frequencies and a risk of resam-
pling (Supplementary Fig. S2).
Amplification steps. A 1009-bp nucleotide fragment encompassing the V1-V3 env region of 
HIV-1 RNA was amplified by RT-PCR. The linearity of the PCR amplification process was checked by 
Figure 3. Example of PyroVir analysis for predicting HIV-1 quasispecies coreceptor usage. RNA 
was extracted from a plasma sample from an HIV-infected subject and submitted to nested RT-PCR 
amplification of V3 env, ultra-deep pyrosequencing, and PyroVir analysis. Ultra-deep pyrosequencing 
provided 2,549 analyzable V3 reads, of which 107 were discarded by the biological filter and and 74 by the 
statistical filter. 2 variants, one accounting for 2.9% and the other for 1% of the quasispecies, were predicted 
to use CXCR4.
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comparing the proportions of X4 (LAI, GenBank accession no. K02013.1) and R5 (JR-CSF, GenBank 
accession no. M38429.1) clones in the pyrosequencing output with the input of X4:R5 virus clones 
mixed in proportions of 0:100, 0.5:99.5, 1:99, 5:95, 20:80, 50:50, 75:25, and 100:0, adjusted to a total 
input of 2,000–3,000 copies of RNA, and submitted to multiple parallel PCR amplifications with var-
ious numbers of cycles. The resulting optimized process used the SuperScript III One-Step RT-PCR 
System (Invitrogen) for RT-PCR with the following conditions: 60 min at 55 °C; 2 min at 94 °C; 30 s at 
94 °C, 30 s at 55 °C, and 1 min 30 s at 68 °C for 10 cycles; the annealing temperature was then increased 
to 58 °C for the next 24 cycles, without a final extension step. The following primers were used: forward 
5′ - CCACCACTCTATTTTGTGCATCA-3′ ; reverse 5′ - CAGTAGAAAAATTCCCCTCCACA-3′ . The 
nested PCR of V3 env was performed on pooled products of the first amplification with the Phusion 
High-Fidelity DNA Polymerase (Thermo Scientific) in the presence of DMSO (3%) as follows: 30 s at 
98 °C; 10 s at 98 °C, 30 s at 55 °C, and 20 s at 72 °C for 10 cycles; the annealing temperature was then 
increased to 60 °C for the next 15 cycles without a final extension step. The number of PCR cycles was 
limited to 25 to ensure that the amplification remained linear, as described above. The nested primers 
were specific fusion primers needed to fuse to the emulsion PCR beads required by the 454 technology. 
They also included a 4-nucleotide sequencing key “TCAG” to identify the DNA library, 10-nucleotide 
multiplex identifiers (MIDs) used as a DNA barcode to identify samples after sequencing was com-
plete, and a V3-spanning degenerate sequence (forward 5′ - ACAATGYACACATGGAATTARGCCA 
-3′ ; reverse 5′ - AGAAAAATTCYCCTCYACAATTAAA -3′ ). The amplified PCR products were ana-
lyzed using a LabChip GX (Caliper) and then purified using Agencourt Ampure PCR Purification beads 
(Beckman Coulter) to remove small (< 300 bp) fragments. The purified PCR products were the quantified 
using a Quant-iT Picogreen dsDNA Assay Kit (Invitrogen) on a LightCycler 480 (Roche) and diluted to 
a concentration of 1 × 109 molecules/μ l.
V3 env ultra-deep pyrosequencing. Ultra-deep pyrosequencing was performed on a 454 GS Junior. 
PCR amplicons were combined and clonally amplified on DNA capture beads in water-in-oil emulsion 
micro-reactors at a ratio of 0.4 copies per capture bead. A total of 500,000 enriched-DNA beads were 
thus deposited in the wells of a full GS Junior Titanium PicoTiterPlate device and pyrosequenced in both 
forward and reverse directions. Bases were flowed sequentially and always in the same order (TCAG) 
across the wells of the PicoTiterPlate device during a 10-hour sequencing run generating long (500 bp) 
sequences.
Genotypic prediction of HIV-1 coreceptor usage from V3 ultra-deep pyrosequencing 
data. The sequences of the V3 env regions were first processed using GS Amplicon Variant Analyzer 
(AVA) software, version 2.5 p1 (Roche). This software extracts sequences from the standard flowgram 
format (SFF) files generated after pyrosequencing and automatically assigns each read to the proper 
sample by looking for the MIDs located at both ends of V3. Only sequences with an average phred 
equivalent quality score > Q30 were conserved. Moreover, only sequences that had been read in both 
senses were used for further analyses. The MIDs and primer sequences within the read have also to be 
complete without mismatch. Moreover, the reads have to match the full-length amplicon The sequence 
reads were aligned with the BaL consensus sequence (GenBank accession no. AY426110.1) and processed 
using an in-house automated data cleaning strategy (see Results) rather than the AVA filters. We used 
the combined 11/25 and net charge rule to infer the tropism of each virus clone from the V3 amino acid 
sequence. It requires one of the following criteria for predicting the CXCR4 coreceptor usage of HIV-1 
subtype B21,23: (i) an R or K at position 11 of V3 and/or a K at position 25; (ii) an R at position 25 of V3 
and a net charge of at least + 5; and (iii) a net charge of at least + 6. The V3 net charge was calculated 
by subtracting the number of negatively charged amino acids (D and E) from the number of positively 
charged ones (K and R). Subtype-specific algorithms derived from the combined 11/25 and net charge 
rule have been developed for subtypes D, and CRF01-AE38,39.
Determining the global error rate of ultra-deep pyrosequencing of V3. We estimated the fre-
quency of errors introduced during V3 amplification and GS Junior pyrosequencing by comparing the 
pyrosequencing reads to the Sanger sequences of 20 plasmid clones of env obtained from HIV-1 subtype 
B primary isolates. We first determined the frequency of artifactual V3 variants among the reads of each 
virus clone. The global error rate of ultra-deep pyrosequencing was then defined as the upper limit of 
the 99% confidence interval (Poisson statistics) of the mean frequency of artifactual V3 variants among 
the reads of the 20 clones.
Poisson distribution was applied to this global error rate to assess the risk of an artifactual V3 sequence 
being an authentic variant. We calculated the probability that a minor variant with n occurrences in N 
reads would occur n or more times if it was an error, using the following formula:
∑ λ= −
!
×
( )
λ
=
− −
P e
k
1
1k
n
k
1
1
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Here, λ is the expected number of artifactual sequences given N reads and is calculated by λ = N * μ, with 
μ being the global error rate (defined above). Only those variants whose frequency of occurrence yielded 
a P value of < 0.001 according to the Poisson model were considered authentic.
Determining the position-specific error rates of ultra-deep pyrosequencing along the V3 
sequence. As the errors generated during ultra-deep pyrosequencing are sequence-dependant, we 
determined specific error rates at each position in V3. We measured the mean codon error rate among 
the 20 clones at each V3 position. The position-specific error rates were then defined as the upper limit 
of the 99% confidence interval (Poisson statistics) of the mean frequency of artifactual codons among 
the 20 clones at each position of V3. We then determined weighted error rates to construct a sensitivity 
threshold matrix at each position of V3 to identify authentic virus variants harboring a point mutations 
for a given number of reads with P < 0.001.
Sensitivities of phenotyping and ultra-deep pyrosequencing for detecting and quantifying 
minor CXCR4-using variants. We assessed the capacity of ultra-deep pyrosequencing to detect and 
correctly quantify minor CXCR4-using variants in a virus population of CCR5-using variants using 
artificial mixtures of X4 and R5 virus clones that were phenotyped in parallel using the ultrasensitive 
TTT phenotypic assay8. Three artificial mixtures of X4 and R5 virus clones were used: LAI (GenBank 
accession no. K02013.1, X4 phenotype) and JR-CSF (GenBank accession no., R5 phenotype); AFG04 
(GenBank accession no. DQ136796.1, X4 phenotype) and AFG01 (GenBank accession no. DQ136807.1, 
R5 phenotype); CHS02 (GenBank accession no. DQ136867.1, X4 phenotype) and CHS11 (GenBank 
accession no. DQ136859.1, R5 phenotype). AFG and CHS are primary HIV-1 isolates that had previ-
ously been cloned and phenotyped for CCR5 anf CXCR4 coreceptor usage47. The HIV-1 RNA in culture 
supernatants of the pure R5 and X4 clones was quantified using the COBAS Ampliprep/COBAS TaqMan 
HIV-1 test version 2.0 (Roche), and then mixed in defined proportions of X4:R5 viruses (0:100; 0.5:99.5; 
1:99; 5:95; 20:80; 50:50; 75:25; and 100:0, each with 2–3 replicates). RNA was then extracted, adjusted 
to a total of 3,000 virus copies/reaction in triplicate, and submitted to ultra-deep pyrosequencing and 
phenotyping in parallel.
Statistics. Poisson statistics were calculated using R version 3.0.0.
Langage programming. PyroVir was written in the Java programming language and run with the 
Java 6.25 software.
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